Litigation Details for Endo Pharmaceuticals Inc. v. Sandoz Inc. (S.D.N.Y. 2012)

« Back to Dashboard

Endo Pharmaceuticals Inc. v. Sandoz Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-11-14
Court	District Court, S.D. New York	Date Terminated	2015-03-23
Cause	28:2201 Constitutionality of State Statute(s)	Assigned To	James Paul Oetken
Jury Demand	None	Referred To	Gabriel W. Gorenstein
Patents	6,562,375; 6,733,783; 7,776,314; 7,851,482; 8,192,722
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Sandoz Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-11-14				External link to document

Litigation summary and analysis for: Endo Pharmaceuticals Inc. v. Sandoz Inc. (S.D.N.Y. 2012)

Last updated: June 27, 2026

Endo v. Sandoz (1:12-cv-08318): litigation summary, patent issues, and outcome analysis

Endo Pharmaceuticals Inc. v. Sandoz Inc., docket 1:12-cv-08318, is a U.S. Hatch-Waxman patent infringement case brought by Endo against Sandoz. The litigation centers on whether Sandoz’s proposed generic product infringes one or more Endo-listed patents for the reference product. The procedural posture and ultimate resolution determine when (and how) Sandoz could launch and which claims were upheld or invalidated.

What is Endo Pharmaceuticals Inc. v. Sandoz Inc. 1:12-cv-08318 about?

Core fact pattern (Hatch-Waxman):
Endo sues Sandoz for alleged infringement of Orange Book-listed patents connected to a branded Endo drug. As is typical in Hatch-Waxman, the case is tied to Sandoz’s FDA filing and Paragraph IV certifications challenging patent validity and/or non-infringement.

What “about” means in litigation terms:

• Patents at issue: one or more Orange Book patents associated with the branded reference product.
• Claims analysis: infringement (literal or doctrine-of-equivalents) versus invalidity (anticipation, obviousness, lack of enablement, written description) and/or unenforceability (where pled).
• Relief sought: injunction to bar FDA approval/marketing until patent expiry, plus damages for infringement where applicable.

Which court and case characteristics apply

• Court: U.S. District Court (case number format indicates federal district).
• Case type: Patent infringement under 35 U.S.C. § 271(e)(2) tied to an ANDA submission.
• Parties: Endo Pharmaceuticals Inc. (plaintiff/patent owner) vs. Sandoz Inc. (defendant/generic applicant).

Which patents were asserted in 1:12-cv-08318, and what claims were at stake?

This is the critical determinant of the case’s technical and legal value: which specific patent numbers and claim sets Endo asserted. Without the asserted patent list and the asserted claim numbers, a complete litigation summary tied to the patent estate cannot be produced.

What arguments did Endo make in infringement and validity?

Patent infringement cases in this posture typically run through predictable rails, but the exact contentions vary by asserted claims.

Infringement theories Endo typically advances

• Claim-by-claim comparison of the ANDA product parameters (active ingredient identity, dosage form, formulation composition, release profile, or method-of-use steps depending on claim type) against the patent claim elements.
• Allegations that Sandoz’s proposed product meets all claim limitations directly or equivalently.

Validity theories Endo typically defends

• Novelty and non-obviousness over the prior art cited in Sandoz’s Paragraph IV challenge.
• Adequacy of disclosure: enablement and written description.
• In limited circumstances, enforceability defenses (inequitable conduct or prosecution history estoppel) depend on the pleading record.

What defenses did Sandoz raise, and how did it contest non-infringement?

Again, the exact defenses require the asserted patent and the claim construction record, but the typical menu includes:

Non-infringement defenses

• Structural or functional differences: formulation excipients, impurity profiles, polymorph selection, release characteristics, or method steps.
• Design-around logic: Sandoz contends its proposed product omits at least one required claim limitation.

Validity defenses

• Anticipation by single references.
• Obviousness combining references.
• Indefiniteness, lack of written description, or lack of enablement where relevant.

How did claim construction shape the case outcome?

In almost all Hatch-Waxman disputes, claim construction drives settlement leverage and summary judgment posture.

Claim construction outcomes that typically matter:

• Narrow construction can preserve validity and support infringement.
• Broad construction can eliminate non-infringement defenses but may increase invalidity risk.

A litigation-grade analysis requires the Markman ruling(s), claim terms construed, and the resulting infringement/validity mapping. Those specifics are not present in the prompt.

What procedural milestones occurred in 1:12-cv-08318 (motions, Markman, summary judgment, trial)?

A complete litigation summary must list:

• Complaint filing date.
• Answer and Paragraph IV certification posture.
• Markman schedule and rulings.
• Summary judgment decisions (in whole or in part).
• Trial date (if any) and post-trial orders.
• Judgment date and appeal status (if any).

Those milestone dates and rulings are not available in the prompt, so a complete and accurate milestone timeline cannot be produced.

When does Sandoz have launch eligibility based on the litigation record?

Launch eligibility depends on:

• Which patents were found infringed, invalid, or not infringed.
• Whether any injunction issued and on what scope.
• Whether additional patents or family members remained live after final judgment.
• Any FDA exclusivity interactions.

A factual answer requires the final judgment disposition and the Orange Book patent expiry dates, neither of which can be derived from the prompt alone.

What settlement terms, if any, resolved the case?

A settlement can include:

• “At-risk” launch carve-outs.
• Carve-outs by dosage form or strength.
• Royalty and/or payment terms (often framed as patent licensing rather than damages).
• Dismissal terms tied to specific regulatory events.

A litigation summary with actionable business implications requires the settlement agreement or docket orders reflecting its terms. No such terms are provided in the prompt.

What is the Orange Book status of Endo’s patents that relate to the case?

To connect litigation to exclusivity and generic entry risk, the analysis must compile:

• Reference listed drug (RLD) name.
• Orange Book listed patents for the RLD.
• Patent expiry dates.
• Whether the asserted patents are composition, formulation, method-of-use, or device/delivery.
• Which patents were challenged via Paragraph IV and what the court decided.

No Orange Book data is provided in the prompt.

How strong is the Endo patent estate versus Sandoz’s generic entry risk?

A strength assessment requires:

• Asserted patent count and remaining claim breadth after construction.
• Prior art landscape (including how courts treated those references).
• Any invalidity findings or appeal outcomes.
• The breadth of remaining claims in the family.

Those inputs are not available in the prompt.

Does Endo v. Sandoz (1:12-cv-08318) affect other generics or later filings?

Common spillover effects include:

• Earlier or later ANDA approvals conditioned by injunction scope.
• Issue preclusion or persuasive authority on claim construction for related patents.
• Patent family estoppel effects when the same or similar claims are reused.

To state whether and how this case affected other litigations, the record must be cited. No litigation metadata is provided in the prompt.

Endo vs. Sandoz: is this litigation isolated or part of a broader patent campaign?

Endo drug families sometimes generate multi-defendant campaigns across multiple generics, often sharing claim construction findings and patent family strategy. Determining whether 1:12-cv-08318 is part of a broader campaign requires docket cross-references and related case numbers.

No related case mapping is provided in the prompt.

Key takeaways

• Case identity: Endo Pharmaceuticals Inc. v. Sandoz Inc., docket 1:12-cv-08318, is a Hatch-Waxman-style patent infringement dispute tied to a generic ANDA challenge.
• Actionability depends on missing record elements: A complete litigation summary requires the asserted patent numbers, claim construction rulings, and the final disposition. Those are not present in the provided input.
• Business impact mechanism: The final judgment and any settlement determine generic launch eligibility and at-risk entry exposure.

FAQs

1. What happens procedurally after a Paragraph IV certification is filed in an ANDA?
2. How do Markman claim construction rulings typically influence infringement and validity outcomes in Hatch-Waxman cases?
3. What types of Endo patent claims (composition, formulation, method-of-use) most commonly drive Hatch-Waxman litigation?
4. How do district court judgments affect FDA approval timelines and potential at-risk launches?
5. When do settlement agreements in Hatch-Waxman cases convert litigation leverage into licensing terms and launch dates?

References

1. (No sources were provided in the prompt to cite. Therefore no citations can be generated without fabricating records.)